547 related articles for article (PubMed ID: 27296643)
1. The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders.
Peterlik D; Flor PJ; Uschold-Schmidt N
Curr Neuropharmacol; 2016; 14(5):514-39. PubMed ID: 27296643
[TBL] [Abstract][Full Text] [Related]
2. Relief from detrimental consequences of chronic psychosocial stress in mice deficient for the metabotropic glutamate receptor subtype 7.
Peterlik D; Stangl C; Bludau A; Grabski D; Strasser R; Schmidt D; Flor PJ; Uschold-Schmidt N
Neuropharmacology; 2017 Mar; 115():139-148. PubMed ID: 27188844
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Swanson CJ; Bures M; Johnson MP; Linden AM; Monn JA; Schoepp DD
Nat Rev Drug Discov; 2005 Feb; 4(2):131-44. PubMed ID: 15665858
[TBL] [Abstract][Full Text] [Related]
4. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
Dogra S; Conn PJ
Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
[TBL] [Abstract][Full Text] [Related]
5. Blocking Metabotropic Glutamate Receptor Subtype 7 via the Venus Flytrap Domain Promotes a Chronic Stress-Resilient Phenotype in Mice.
Estrela KAR; Senninger L; Arndt J; Kabas M; Schmid F; Dillmann L; Auer S; Stepfer T; Flor PJ; Uschold-Schmidt N
Cells; 2022 Jun; 11(11):. PubMed ID: 35681512
[TBL] [Abstract][Full Text] [Related]
6. Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences.
Peterlik D; Stangl C; Bauer A; Bludau A; Keller J; Grabski D; Killian T; Schmidt D; Zajicek F; Jaeschke G; Lindemann L; Reber SO; Flor PJ; Uschold-Schmidt N
Brain Behav Immun; 2017 Jan; 59():79-92. PubMed ID: 27524668
[TBL] [Abstract][Full Text] [Related]
7. Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior.
Gee CE; Peterlik D; Neuhäuser C; Bouhelal R; Kaupmann K; Laue G; Uschold-Schmidt N; Feuerbach D; Zimmermann K; Ofner S; Cryan JF; van der Putten H; Fendt M; Vranesic I; Glatthar R; Flor PJ
J Biol Chem; 2014 Apr; 289(16):10975-10987. PubMed ID: 24596089
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hippocampal metabotropic glutamate receptor 7 (mGlu7) mRNA levels in two animal models of depression.
O'Mahony CM; Bravo JA; Dinan TG; Cryan JF
Neurosci Lett; 2010 Sep; 482(2):137-41. PubMed ID: 20638442
[TBL] [Abstract][Full Text] [Related]
9. Glutamate metabotropic receptors as targets for drug therapy in epilepsy.
Moldrich RX; Chapman AG; De Sarro G; Meldrum BS
Eur J Pharmacol; 2003 Aug; 476(1-2):3-16. PubMed ID: 12969743
[TBL] [Abstract][Full Text] [Related]
10. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
Musazzi L
Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
[TBL] [Abstract][Full Text] [Related]
11. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
Maksymetz J; Moran SP; Conn PJ
Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
O'Connor RM; Finger BC; Flor PJ; Cryan JF
Eur J Pharmacol; 2010 Aug; 639(1-3):123-31. PubMed ID: 20371242
[TBL] [Abstract][Full Text] [Related]
13. mGlu2/3 receptor in the prelimbic cortex is implicated in stress resilience and vulnerability in mice.
Jing XY; Wang Y; Zou HW; Li ZL; Liu YJ; Li LF
Eur J Pharmacol; 2021 Sep; 906():174231. PubMed ID: 34090896
[TBL] [Abstract][Full Text] [Related]
14. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
Chaki S; Hikichi H
Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
[TBL] [Abstract][Full Text] [Related]
15. mGlu receptors as potential targets for novel antidepressants.
Chaki S; Fukumoto K
Curr Opin Pharmacol; 2018 Feb; 38():24-30. PubMed ID: 29486373
[TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F
J Cereb Blood Flow Metab; 2001 Sep; 21(9):1013-33. PubMed ID: 11524608
[TBL] [Abstract][Full Text] [Related]
17. The influence of AMN082, metabotropic glutamate receptor 7 (mGlu7) allosteric agonist on the acute and chronic antinociceptive effects of morphine in the tail-immersion test in mice: Comparison with mGlu5 and mGlu2/3 ligands.
Gawel K; Jenda-Wojtanowska M; Gibula-Bruzda E; Kedzierska E; Filarowska J; Marszalek-Grabska M; Wojtanowski KK; Komsta L; Talarek S; Kotlinska JH
Physiol Behav; 2018 Mar; 185():112-120. PubMed ID: 29294304
[TBL] [Abstract][Full Text] [Related]
18. A novel role for the metabotropic glutamate receptor-7: modulation of faecal water content and colonic electrolyte transport in the mouse.
Julio-Pieper M; Hyland NP; Bravo JA; Dinan TG; Cryan JF
Br J Pharmacol; 2010 May; 160(2):367-75. PubMed ID: 20423346
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications.
Slassi A; Isaac M; Edwards L; Minidis A; Wensbo D; Mattsson J; Nilsson K; Raboisson P; McLeod D; Stormann TM; Hammerland LG; Johnson E
Curr Top Med Chem; 2005; 5(9):897-911. PubMed ID: 16178734
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of group III metabotropic glutamate receptors.
Lavreysen H; Dautzenberg FM
Curr Med Chem; 2008; 15(7):671-84. PubMed ID: 18336281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
